- X-Chem, the provider of innovative solutions in early-stage drug discovery, has announced the expansion of its collaboration with Kymera Therapeutics ( NASDAQ: KYMR ).
- With the expanded agreement, X-Chem will serve as the primary provider of DNA-encoded library-based screening services to Kymera, with X-Chem applying its world-leading DEL platform to support Kymera’s discovery of first- and best-in-class protein degraders.
- The expanded partnership comprises 12 targets and grants Kymera exclusive rights to compounds discovered within the collaboration.
- “Kymera’s unique target selection strategy is critical to our success, and X-Chem has been a valued partner in helping us to unlock challenging disease targets that can be only or best addressed by targeted protein degradation." said Nello Mainolfi, Ph.D., Founder, President and CEO of Kymera Therapeutics.
For further details see:
Kymera Therapeutics and X-Chem a expand existing partnership